Vitamin D is typically viewed as a key player in the regulation of calcium and phosphate levels and the control of bone metabolism; however, growing evidence suggests that vitamin D deficiency may also have an important role in the progressive loss of renal function. Vitamin D deficiency is particularly frequent in patients with chronic kidney disease, in whom it is associated with increased mortality. Studies indicate that treatment with vitamin D analogues reduces proteinuria, suppresses the renin–angiotensin–aldosterone system (RAAS), and exerts anti-inflammatory and immunomodulatory effects. These pleiotropic effects render vitamin D a potentially interesting treatment modality for renoprotection in patients with chronic kidney disease. Whether vitamin D has clinically relevant renoprotective effects in addition to RAAS blockade is currently under investigation.
Inadequate vitamin D levels are present in the majority of Western populations, but vitamin D deficiency is more prevalent and severe in patients with chronic kidney disease (CKD)
Decreased circulating levels of active vitamin D in patients with CKD may be explained by suppression of renal 1α-hydroxylase activity
Vitamin D deficiency has been associated with increased mortality, increased cardiovascular disease and increased risk of fracture
Vitamin D analogues might ameliorate the reactive rise in renin observed in patients with CKD treated with suppression of the renin–angiotensin–aldosterone system
The antiproteinuric effect of active vitamin D has been confirmed in preclinical studies of CKD and clinical trials to investigate this effect are ongoing
Vitamin D has anti-inflammatory and immunomodulatory effects, suggesting that treatment with vitamin D analogues may be particularly beneficial in patients with glomerulonephritis, autoimmune diseases, and renal transplant recipients
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266–281 (2007).
Nykjaer, A. et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96, 507–515 (1999).
Zhong, Y., Armbrecht, H. J. & Christakos, S. Calcitonin, a regulator of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene. J. Biol. Chem. 284, 11059–11069 (2009).
Turunen, M. M., Dunlop, T. W., Carlberg, C. & Vaisanen, S. Selective use of multiple vitamin D response elements underlies the 1 alpha, 25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Res. 35, 2734–2747 (2007).
Liu, S. et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17, 1305–1315 (2006).
Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774 (2006).
Shimada, T. et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113, 561–568 (2004).
Carlberg, C. & Seuter, S. A genomic perspective on vitamin D signaling. Anticancer Res. 29, 3485–3493 (2009).
Christakos, S., Raval-Pandya, M., Wernyj, R. P. & Yang, W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem. J. 316 (Pt 2), 361–371 (1996).
Ginde, A. A., Liu, M. C. & Camargo, C. A. Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch. Intern. Med. 169, 626–632 (2009).
White, J. H. Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis. J. Steroid Biochem. Mol. Biol. 89–90, 239–244 (2004).
Bosse, Y., Maghni, K. & Hudson, T. J. 1alpha, 25-dihydroxy-vitamin D3 stimulation of bronchial smooth muscle cells induces autocrine, contractility, and remodeling processes. Physiol. Genomics 29, 161–168 (2007).
Ellis, B. C., Gattoni-Celli, S., Mancia, A. & Kindy, M. S. The vitamin D3 transcriptomic response in skin cells derived from the Atlantic bottlenose dolphin. Dev. Comp. Immunol. 33, 901–912 (2009).
Towsend, K. et al. Identification of VDR-responsive gene signatures in breast cancer cells. Oncology 71, 111–123 (2006).
Wu-Wong, J. R., Nakane, M., Ma, J., Ruan, X. & Kroeger, P. E. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J. Cell Biochem. 100, 1395–1405 (2007).
Tan, X., Wen, X. & Liu, Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol. 19, 1741–1752 (2008).
Norman, A. W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147, 5542–5548 (2006).
Dusso, A. S., Brown, A. J. & Slatopolsky, E. Vitamin D. Am. J. Physiol. Renal Physiol. 289, F8–F28 (2005).
Holick, M. F. & Garabedian, M. in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (ed. Favus, M. J.) 129–137 (Lippincott Williams & Wilkins, Washington, DC, 2006).
Holick, M. F. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest. 116, 2062–2072 (2006).
Kumar, R., Schaefer, J., Grande, J. P. & Roche, P. C. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am. J. Physiol. 266, F477–F485 (1994).
Zhang, Z. et al. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 72, 193–201 (2007).
Zhang, Z. et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 73, 163–171 (2008).
Vieth, R. The role of vitamin D in the prevention of osteoporosis. Ann. Med. 37, 278–285 (2005).
Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T. & Dawson-Hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18–28 (2006).
Lips, P. Which circulating level of 25-hydroxyvitamin D is appropriate? J. Steroid Biochem. Mol. Biol. 89–90, 611–614 (2004).
Malabanan, A., Veronikis, I. E. & Holick, M. F. Redefining vitamin D insufficiency. Lancet 351, 805–806 (1998).
Jones, G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 88, 582S–586S (2008).
Matsuoka, L. Y., Ide, L., Wortsman, J., MacLaughlin, J. A. & Holick, M. F. Sunscreens suppress cutaneous vitamin D3 synthesis. J. Clin. Endocrinol. Metab. 64, 1165–1168 (1987).
Scragg, R. & Camargo, C. A. Jr. Frequency of leisure-time physical activity and serum 25-hydroxyvitamin D levels in the US population: results from the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 168, 577–586 (2008).
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z. & Holick, M. F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72, 690–693 (2000).
Binkley, N. et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J. Clin. Endocrinol. Metab. 89, 3152–3157 (2004).
Singh, R. J. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D? Clin. Chem. 54, 221–223 (2008).
Yates, A. M. et al. Interlaboratory variation in 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is significantly improved if common calibration material is used. Clin. Chem. 54, 2082–2084 (2008).
Looker, A. C. et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am. J. Clin. Nutr. 88, 1519–1527 (2008).
Carter, G. D. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin. Chem. 55, 1300–1302 (2009).
Gonzalez, E. A., Sachdeva, A., Oliver, D. A. & Martin, K. J. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am. J. Nephrol. 24, 503–510 (2004).
Jean, G., Charra, B. & Chazot, C. Vitamin D deficiency and associated factors in hemodialysis patients. J. Ren. Nutr. 18, 395–399 (2008).
LaClair, R. E. et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am. J. Kidney Dis. 45, 1026–1033 (2005).
Levin, A. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71, 31–38 (2007).
Barreto, D. V. et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1128–1135 (2009).
Cuppari, L., Carvalho, A. B. & Draibe, S. A. Vitamin D status of chronic kidney disease patients living in a sunny country. J. Ren. Nutr. 18, 408–414 (2008).
Wolf, M. et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72, 1004–1013 (2007).
Wang, A. Y. et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am. J. Clin. Nutr. 87, 1631–1638 (2008).
Zittermann, A., Gummert, J. F. & Borgermann, J. Vitamin D deficiency and mortality. Curr. Opin. Clin. Nutr. Metab. Care doi:10.1097/MCO.0b013e3283310767
Autier, P. & Gandini, S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 167, 1730–1737 (2007).
Melamed, M. L., Michos, E. D., Post, W. & Astor, B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168, 1629–1637 (2008).
Wang, T. J. et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503–511 (2008).
Dobnig, H. et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340–1349 (2008).
Hsia, J. et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 115, 846–854 (2007).
Wallis, D. E. & Penckofer, S. Letter by Wallis and Penckofer regarding article, “Calcium/vitamin D supplementation and cardiovascular events”. Circulation 116, e86 (2007).
Pettifor, J. M. in Vitamin D (eds Feldman, D., Pike, J. W. & Glorieux, F. H.) 1065–1084 (Elsevier Academic Press, Boston, 2005).
Avenell, A., Gillespie, W. J., Gillespie, L. D. & O'Connell, D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD000227 doi:10.1002/14651858.CD000227.pub3 (2009).
Tang, B. M., Eslick, G. D., Nowson, C., Smith, C. & Bensoussan, A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657–666 (2007).
Chapuy, M. C. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327, 1637–1642 (1992).
Dawson-Hughes, B., Harris, S. S., Krall, E. A. & Dallal, G. E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337, 670–676 (1997).
Grant, A. M. et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365, 1621–1628 (2005).
de Boer, I. H., Ioannou, G. N., Kestenbaum, B., Brunzell, J. D. & Weiss, N. S. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 50, 69–77 (2007).
Lambers Heerspink, H. J. et al. The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: study design and baseline characteristics. Am. J. Nephrol. 30, 280–286 (2009).
Inaguma, D. et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin. Exp. Nephrol. 12, 126–131 (2008).
Ravani, P. et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 75, 88–95 (2009).
de Boer, I. et al. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J. Am. Soc. Nephrol. 20, 1805–1812 (2009).
Chonchol, M. & Scragg, R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 71, 134–139 (2007).
Martins, D. et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 167, 1159–1165 (2007).
Marcen, R. et al. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients. Transplant. Proc. 39, 2256–2258 (2007).
Pichette, V. et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am. J. Kidney Dis. 28, 105–114 (1996).
Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease [online].
Yuan, W. et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 282, 29821–29830 (2007).
Tan, X., Li, Y. & Liu, Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 17, 3382–3393 (2006).
Leheste, J. R. et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am. J. Pathol. 155, 1361–1370 (1999).
Leheste, J. R. et al. Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J. 17, 247–249 (2003).
Matsui, I. et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol. Dial. Transplant. 24, 2354–2361 (2009).
Jacob, A. I., Sallman, A., Santiz, Z. & Hollis, B. W. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 114, 1313–1319 (1984).
Andress, D. L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 69, 33–43 (2006).
Li, Y., Spataro, B. C., Yang, J., Dai, C. & Liu, Y. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int. 68, 1500–1510 (2005).
Schwarz, U. et al. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 53, 1696–1705 (1998).
Xiao, H. et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am. J. Nephrol. 30, 34–43 (2009).
Okamura, M., Takano, Y., Saito, Y., Yao, J. & Kitamura, M. Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor. Nephrol. Dial. Transplant. 24, 3006–3012 (2009).
Yamauchi, K. et al. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int. 70, 892–900 (2006).
Wang, Y. et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int. 70, 882–891 (2006).
Kuhlmann, A. et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am. J. Physiol. Renal Physiol. 286, F526–F533 (2004).
Li, Y. C. et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110, 229–238 (2002).
Pilz, S., Tomaschitz, A., Ritz, E. & Pieber, T. R. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol. 6, 621–630 (2009).
Morris, K. L. & Zemel, M. B. 1,25-Dihydroxyvitamin D3 modulation of adipocyte glucocorticoid function. Obes. Res. 13, 670–677 (2005).
de Borst, M. H. et al. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab. Invest. 83, 1761–1770 (2003).
van Veldhuisen, D. J. et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J. Am. Coll. Cardiol. 32, 1811–1818 (1998).
Krikken, J. A., Laverman, G. D. & Navis, G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. doi:10.1097/MNH.0b013e3283312fc8
Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D. & Navis, G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19, 999–1007 (2008).
Kramer, A. B., van der Meulen, E. F., van Goor, H. & Navis, G. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int. 71, 417–424 (2007).
Nguyen, G. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417–1427 (2002).
Hamming, I., Navis, G., Kocks, M. J. & van Goor, H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J. Pathol. 209, 129–139 (2006).
Mizobuchi, M. et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J. Am. Soc. Nephrol. 18, 1796–1806 (2007).
van Paassen, P., de Zeeuw, D., Navis, G. & de Jong, P. E. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol. Dial. Transplant. 15, 637–643 (2000).
Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433–2446 (2008).
Persson, F. et al. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 32, 1873–1879 (2009).
Yamamoto, E. et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 54, 633–638 (2009).
Batenburg, W. W. et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 28, 1151–1157 (2008).
Zhang, Z. et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc. Natl Acad. Sci. USA 105, 15896–15901 (2008).
Kramer, A. B., Laverman, G. D., van Goor, H. & Navis, G. Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J. Pathol. 201, 160–167 (2003).
Remuzzi, G. et al. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J. Am. Soc. Nephrol. 10, 1542–1549 (1999).
Panichi, V. et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 60, 87–95 (2001).
Lemire, J. M., Adams, J. S., Sakai, R. & Jordan, S. C. 1 Alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J. Clin. Invest. 74, 657–661 (1984).
Rigby, W. F., Stacy, T. & Fanger, M. W. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J. Clin. Invest. 74, 1451–1455 (1984).
Adams, J. S. & Hewison, M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 4, 80–90 (2008).
Zehnder, D. et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int. 74, 1343–1353 (2008).
Cohen-Lahav, M., Douvdevani, A., Chaimovitz, C. & Shany, S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J. Steroid Biochem. Mol. Biol. 103, 558–562 (2007).
Sigmundsdottir, H. et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8, 285–293 (2007).
Fritsche, J., Mondal, K., Ehrnsperger, A., Andreesen, R. & Kreutz, M. Regulation of 25-hydroxyvitamin D3–1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood 102, 3314–3316 (2003).
van Etten, E. & Mathieu, C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 97, 93–101 (2005).
Mora, J. R., Iwata, M. & von Andrian, U. H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 8, 685–698 (2008).
Penna, G. & Adorini, L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164, 2405–2411 (2000).
Adorini, L. & Penna, G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 70, 345–352 (2009).
Ghoreishi, M. et al. Expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J. Immunol. 182, 6071–6078 (2009).
Redaelli, C. A. et al. 1Alpha, 25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int. 61, 288–296 (2002).
Courbebaisse, M. et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int. 75, 646–651 (2009).
Heymann, F. et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J. Clin. Invest. 119, 1286–1297 (2009).
Thiem, U. et al. VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome. Trials 10, 36 (2009).
M. H. de Borst is supported by research grants from the Dutch Kidney Foundation (KJPB.08.07) and the University Medical Center Groningen (Mandema stipend).
The authors declare no competing financial interests.
About this article
Cite this article
Doorenbos, C., van den Born, J., Navis, G. et al. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 5, 691–700 (2009). https://doi.org/10.1038/nrneph.2009.185
Antiproteinuria Effect of Calcitriol in Patients With Chronic Kidney Disease and Vitamin D Deficiency: A Randomized Controlled Study
Journal of Renal Nutrition (2020)
Nutritional assessment among adult patients with suspected or confirmed active tuberculosis disease in rural India
PLOS ONE (2020)
Novel markers of graft outcome in a cohort of kidney transplanted patients: a cohort observational study
Journal of Nephrology (2019)
Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease
Inflammatory Bowel Diseases (2019)
Association of Vitamin D Levels With Kidney Volume in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Frontiers in Medicine (2019)